Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 25 June 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Repeated tegaserod for IBS with constipation is safe

Research in the latest issue of Gut shows that tegaserod provides rapid and sustained relief of symptoms of irritable bowel syndrome with constipation, both during first and repeated treatment.

News image

fiogf49gjkf04

It has been proposed that treatments for irritable bowel syndrome (IBS) with constipation should provide rapid symptomatic relief.

There have also been proposals that IBS treatments should be intermittent, and effective upon repeated use.

Dr Tack and colleagues evaluated the efficacy and safety of tegaserod on IBS symptoms.

The team also investigated its impact on quality of life and health economic measures.

The research team assessed women of 18 years of age with IBS with constipation according to the Rome II criteria.

The team undertook a prospective, double blind, placebo controlled, randomized trial.

Women with IBS and constipation either received tegaserod 6 mg twice daily or placebo for 1 month.

For relief of abdominal discomfort/pain, 31% of responders used tegaserod
Gut

Patients with at least a partial response entered a treatment free interval.

Upon symptom recurrence, the team re-randomized tegaserod treated patients to tegaserod or placebo for an additional month.

Primary efficacy variables were response, or overall IBS symptoms and abdominal discomfort/pain, to first and repeated treatment.

The research team undertook analysis by intention to treat.

The team reported that 2660 patients and 1191 patients were randomized for first and repeated treatment, respectively.

Tegaserod was superior to placebo for each primary efficacy variable.

In the first treatment, there were 34% responders in the tegaserod group vs 24% with placebo for relief of IBS symptoms.

For relief of abdominal discomfort/pain, there were 31% responders in the tegaserod group vs 22% with placebo.

The team observed that repeated treatment occurred in 45% with tegaserod vs 28% with placebo.

Tegaserod was superior to placebo for every secondary efficacy variable.

The secondary efficacy variables included relief of abdominal discomfort/pain, bloating and constipation; stool frequency and consistency.

The research team observed a response to tegaserod was within the first treatment week.

In addition, the noted that tegaserod produced greater satisfaction, work productivity, and improved quality of life than placebo.

Dr Tack's team concludes, “Tegaserod provides rapid and sustained relief of symptoms of irritable bowel syndrome with constipation both during first and repeated treatment.”

Gut 2005: 54: 1707-13
16 November 2005

Go to top of page Email this page Email this page to a colleague

 31 May 2018 
Diagnostic for NAFLD  
 31 May 2018 
Bile acids and the risks for hepatotoxicity
 31 May 2018 
Rectal cancer female sexuality score
 30 May 2018 
Fungal dysbiosis in cirrhosis
 30 May 2018 
Placebo rates in ulcerative colitis trials
 30 May 2018 
Follow-up testing and colorectal cancer mortality
 29 May 2018 
Organ transplantation donors
 29 May 2018 
Novel therapies for IBD
 29 May 2018 
Helicobacter pylori infection to stomach cancer
 28 May 2018 
Mesalazine in ulcerative colitis
 28 May 2018 
Technology and management of digestive diseases
 28 May 2018 
Therapeutic strategies for HCV
 25 May 2018 
Post‐operative complications in elderly IBD
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Colorectal cancer–specific mortality
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Chronic Hep B
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Symptom assessment in cirrhotic ascites
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
European guidelines on pancreatic cystic neoplasms

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us